Screener
Royalty Pharma RPRX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $674.14M+16.5% | $630.58M+11.0% | $621.99M+4.8% | $609.29M+7.9% | $578.67M+7.7% | ||
| $97.85M-67.4% | $39.79M-21.2% | $50.5M+10,000% | $50.5M+10,000% | $300.5M+60,000% | ||
| $161.89M-9.9% | $159.49M+44.1% | $164.27M+143% | $118.73M+109% | $179.77M+229% | ||
| $541.02M+46.7% | $67.54M+98.3% | $233.61M+0.6% | $182.14M+207% | $368.87M+37.8% | ||
| $133.12M-36.5% | $563.04M+5.4% | $388.38M+7.4% | $427.16M-41.9% | $209.8M-22.2% | ||
| 19.7%-16.5pp | 89.3%-4.7pp | 62.4%+1.5pp | 70.1%-60.1pp | 36.3%-13.9pp | ||
| $93.62M+36.3% | $93.72M+43.6% | $94.17M+43.2% | $79.56M+19.6% | $68.67M+40.1% | ||
| -$51.63M+55.9% | -$94.78M+5.0% | -$32.47M— | $17.06M-76.1% | -$117.16M-55.7% | ||
| $81.49M-12.0% | $468.26M+7.8% | $355.91M+6.4% | $444.21M-44.9% | $92.64M-52.3% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $17.88M-44.4% | $294.69M+23.1% | $214.21M+2.9% | $288.22M-47.0% | $32.18M-68.5% | ||
| 2.7%-2.9pp | 46.7%+4.6pp | 34.4%-0.6pp | 47.3%-49.0pp | 5.6%-13.4pp | ||
| $0.04-42.9% | $0.67+21.8% | $0.50+6.4% | $0.67-44.6% | $0.07-69.6% | ||
| $133.12M-36.5% | $563.04M+5.4% | $388.38M+7.4% | $427.16M-41.9% | $209.8M-22.2% |
FAQ
- What is Royalty Pharma's revenue?
- Royalty Pharma (RPRX) generated $2.5B in revenue over the trailing twelve months, up 10.0% year over year.
- Is Royalty Pharma profitable?
- Royalty Pharma reported $815.0M in net income over the trailing twelve months, a 32.1% net margin.
- What is Royalty Pharma's earnings per share?
- Royalty Pharma's diluted EPS over the trailing twelve months is $1.88.
- Where does Royalty Pharma's income statement data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
